Anticonvulsant and gabapentinoids pharmacotherapy in the multiple sclerosis prodrome: A population-based matched cohort study

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY Multiple sclerosis and related disorders Pub Date : 2024-11-16 DOI:10.1016/j.msard.2024.106167

Himali Bergeron-Vitez , Fardowsa LA Yusuf , Feng Zhu , Yinshan Zhao , Charity Evans , John D Fisk , Ruth Ann Marrie , John LK Kramer , Helen Tremlett

{"title":"Anticonvulsant and gabapentinoids pharmacotherapy in the multiple sclerosis prodrome: A population-based matched cohort study","authors":"Himali Bergeron-Vitez , Fardowsa LA Yusuf , Feng Zhu , Yinshan Zhao , Charity Evans , John D Fisk , Ruth Ann Marrie , John LK Kramer , Helen Tremlett","doi":"10.1016/j.msard.2024.106167","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Before disease onset, multiple sclerosis (MS) persons fill more prescriptions than controls, including for pain. However, knowledge regarding neuropathic pain-related medications is lacking</div></div><div><h3>Objective</h3><div>Compare odds of anticonvulsant/gabapentinoid prescriptions for 4,862 MS-cases versus 22,669 controls, pre-MS onset (defined as first demyelinating disease-related event).</div></div><div><h3>Methods</h3><div>Matched-cohort study using administrative data (1996–2013), comparing the odds of anticonvulsant/gabapentinoid prescriptions pre-MS onset using multivariable logistic regression.</div></div><div><h3>Results</h3><div>Versus controls, MS-cases were more likely to fill prescriptions for anticonvulsants (aOR[adjusted odds ratios] = 3.1,95 % confidence interval[CI]:2.8,3.4), gabapentinoids (aOR = 4.1,95 %CI:3.6,4.6), and gabapentinoids without anticonvulsants (aOR = 3.9,95 %CI:3.4,4.5).</div></div><div><h3>Conclusion</h3><div>MS-cases filled anticonvulsant and gabapentinoid prescriptions more than matched controls pre-MS onset.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"93 ","pages":"Article 106167"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034824007430","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Before disease onset, multiple sclerosis (MS) persons fill more prescriptions than controls, including for pain. However, knowledge regarding neuropathic pain-related medications is lacking

Objective

Compare odds of anticonvulsant/gabapentinoid prescriptions for 4,862 MS-cases versus 22,669 controls, pre-MS onset (defined as first demyelinating disease-related event).

Methods

Matched-cohort study using administrative data (1996–2013), comparing the odds of anticonvulsant/gabapentinoid prescriptions pre-MS onset using multivariable logistic regression.

Results

Versus controls, MS-cases were more likely to fill prescriptions for anticonvulsants (aOR[adjusted odds ratios] = 3.1,95 % confidence interval[CI]:2.8,3.4), gabapentinoids (aOR = 4.1,95 %CI:3.6,4.6), and gabapentinoids without anticonvulsants (aOR = 3.9,95 %CI:3.4,4.5).

Conclusion

MS-cases filled anticonvulsant and gabapentinoid prescriptions more than matched controls pre-MS onset.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗惊厥药和加巴喷丁类药物治疗多发性硬化症前驱症状：一项基于人群的匹配队列研究

背景：在发病前，多发性硬化症（MS）患者比对照组服用更多的处方，包括治疗疼痛。然而，关于神经性疼痛相关药物的知识缺乏。目的比较4862例多发性硬化症患者与22669例对照组的抗惊厥药/加巴喷丁类药物处方的几率，多发性硬化症发病前（定义为首次脱髓鞘疾病相关事件）。方法采用匹配队列研究（1996-2013），采用多变量logistic回归比较ms发病前抗惊厥药/加巴喷丁类药物处方的几率。结果与对照组相比，ms病例更倾向于处方抗惊厥药（aOR[校正优势比]= 3.1,95%可信区间[CI]:2.8,3.4）、加巴喷丁类药物（aOR = 4.1, 95% CI:3.6,4.6）和加巴喷丁类药物不含抗惊厥药（aOR = 3.9, 95% CI:3.4,4.5）。结论ms发病前服用抗惊厥药和加巴喷丁类药物的患者多于对照组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Multiple sclerosis and related disorders CLINICAL NEUROLOGY-

CiteScore

5.80

自引率

20.00%

发文量

814

审稿时长

66 days

期刊介绍： Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource. A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.